Viridian Therapeutics Inc logo

Viridian Therapeutics Inc

1
NAS:VRDN (USA)  
$ 13.89 +0.94 (+7.26%) 10:08 PM EST
At Loss
P/B:
2.32
Market Cap:
$ 886.49M
Enterprise V:
$ 433.45M
Volume:
1.11M
Avg Vol (2M):
1.03M
Trade In:
Volume:
1.11M
At Loss
Avg Vol (2M):
1.03M

Business Description

Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Name Current Vs Industry Vs History
Cash-To-Debt 29.12
Equity-to-Asset 0.92
Debt-to-Equity 0.04
Debt-to-EBITDA -0.1
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 8.65
Distress
Grey
Safe
Beneish M-Score -2.18
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 82.42
9-Day RSI 69.47
14-Day RSI 61.64
6-1 Month Momentum % -42.82
12-1 Month Momentum % -37.01

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 23.99
Quick Ratio 23.99
Cash Ratio 23.47

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -133.7
Shareholder Yield % -23.99

Financials (Next Earnings Date:2024-08-08 Est.)

VRDN's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:VRDN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Viridian Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.288
EPS (TTM) ($) -4.5
Beta 0.81
Volatility % 65.33
14-Day RSI 61.64
14-Day ATR ($) 0.747302
20-Day SMA ($) 12.634
12-1 Month Momentum % -37.01
52-Week Range ($) 10.925 - 24.18
Shares Outstanding (Mil) 63.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Viridian Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Viridian Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Viridian Therapeutics Inc Frequently Asked Questions

What is Viridian Therapeutics Inc(VRDN)'s stock price today?
The current price of VRDN is $13.89. The 52 week high of VRDN is $24.18 and 52 week low is $10.93.
When is next earnings date of Viridian Therapeutics Inc(VRDN)?
The next earnings date of Viridian Therapeutics Inc(VRDN) is 2024-08-08 Est..
Does Viridian Therapeutics Inc(VRDN) pay dividends? If so, how much?
Viridian Therapeutics Inc(VRDN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1